If there are no dose-limiting toxicities, the company will test the CAR T-cell therapy at higher doses in more patients with FLT3-expressing refractory AML.

The firm will pick two lead agents targeting PSMA and CLDN18.2 later this year and a third STEAP1-targeting drug next year.

SNUG01 showed favorable safety and signs of early clinical efficacy in a recently completed investigator-initiated trial in China, the firm said.

At least 139 funded projects have focused on precision medicine since the council began awarding the grants in 2011, ...

The company will instead focus resources on its last remaining clinical asset, PRT7732, a chemically distinct SMARCA2 degrader.

Sarepta will sell back $50 million worth of shares to cover part of a $100 million milestone payment and its remaining shares worth $174 million.

BUFFALO, New York – Five major research centers in New York have banded together to share resources and a manufacturing ...

The firm now expects its cash runway to extend to 2028, bolstered by having recently raised $244 million via a private placement and an at-the-market issuance.

The EMA's CHMP said the single pivotal US trial could serve as the basis for a marketing authorization application in the EU.

Researchers at three Boston institutions are advancing a ctDNA assay with the goal of getting more children with solid tumors into biomarker-directed therapies and trials.

Even though oncology segment revenue inched up just 1 percent year over year, the firm lifted full-year expectations slightly ...

The firm will explore FORX-428's activity in patients whose tumors harbor DNA damage repair mutations or mutations that cause high DNA replication stress.